Overview
Mycetoma, also known as Madura foot or maduromycosis, is a chronic, progressive, and destructive subcutaneous infection caused by certain species of fungi (eumycetoma) or filamentous bacteria (actinomycetoma). It is classified as a neglected tropical disease by the World Health Organization. The disease typically affects the foot but can involve any part of the body, including the hands, back, and other extremities. It is acquired through traumatic inoculation of the causative organism into the skin, often via thorns, splinters, or other penetrating injuries. Mycetoma is most prevalent in tropical and subtropical regions, particularly in the so-called "mycetoma belt" stretching across Africa, the Middle East, and parts of Asia and Latin America. The hallmark clinical triad of mycetoma consists of a painless subcutaneous mass (tumefaction), multiple draining sinuses, and the discharge of grains (colonies of the causative organism). The disease progressively involves deeper tissues including fascia, muscle, and bone, leading to significant tissue destruction and deformity. If left untreated, it can cause severe disability and may necessitate amputation. The infection primarily affects the musculoskeletal system and skin. Secondary bacterial infections of the sinuses are common and can cause pain and systemic illness. Treatment depends on the causative agent. Actinomycetoma generally responds well to prolonged courses of combined antibiotic therapy, typically including trimethoprim-sulfamethoxazole with amikacin or other agents, administered for months to years. Eumycetoma is more challenging to treat and often requires prolonged antifungal therapy (such as itraconazole, voriconazole, or posaconazole) combined with surgical excision. In advanced cases with extensive bone involvement, amputation may be the only option. Early diagnosis and treatment are critical to improving outcomes and preventing disability.
Also known as:
Clinical phenotype terms— hover any for plain English:
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
1 eventData sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Mycetoma.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Mycetoma.
Community
No community posts yet. Be the first to share your experience with Mycetoma.
Start the conversation →Latest news about Mycetoma
Disease timeline:
New recruiting trial: Mycetoma Retrospective Data Collection
A new clinical trial is recruiting patients for Mycetoma
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Mycetoma
What is Mycetoma?
Mycetoma, also known as Madura foot or maduromycosis, is a chronic, progressive, and destructive subcutaneous infection caused by certain species of fungi (eumycetoma) or filamentous bacteria (actinomycetoma). It is classified as a neglected tropical disease by the World Health Organization. The disease typically affects the foot but can involve any part of the body, including the hands, back, and other extremities. It is acquired through traumatic inoculation of the causative organism into the skin, often via thorns, splinters, or other penetrating injuries. Mycetoma is most prevalent in trop
At what age does Mycetoma typically begin?
Typical onset of Mycetoma is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Mycetoma?
Yes — 1 recruiting clinical trial is currently listed for Mycetoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Mycetoma?
7 specialists and care centers treating Mycetoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.